Sanofi Competitors and Similar CompaniesClear all
Sanofi's competitors and similar companies include Viatris, AstraZeneca, Lilly, AbbVie, Pfizer, Novartis, Merck and Teva Pharmaceuticals.
 Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Viatris Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products. |  AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Lilly Eli Lilly is a company that discovers, develops, manufactures, and markets pharmaceutical products. |  AbbVie AbbVie is a pharmaceutical company engaged in the research, development, manufacturing, commercialization, and sale of medicines and therapies. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Merck Merck (also known as MSD) is a company that develops and manufactures medicines and vaccines for human and animal health. | ||
Founding Date | Founding Date 1994 | Founding Date 2020 | Founding Date 1999 | Founding Date 1876 | Founding Date 2013 | Founding Date 1849 | Founding Date 1996 | Founding Date 1891 | Founding Date 1901 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||||
Locations | Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more | Locations Canonsburg, US HQ Carole Park, AU Millers Point, AU Campos Dos Goytacazes, BR São Paulo, BR Sofia, BG Toronto, CA see more | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | Locations Indianapolis, US HQ Buenos Aires, AR Sydney, AU Wien, AT Brussel, BE São Paulo, BR Toronto, CA see more | Locations North Chicago, US HQ Hydra, DZ Buenos Aires, AR Mascot, AU Wien, AT Wavre, BE Sarajevo, BA see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Rahway, US HQ Munro, AR Macquarie Park, AU Krems An Der Donau, AT Wien, AT Bruxelles, BE Santa Cruz De La Sierra, BO see more | Locations Petah Tikva, IL HQ Villa Adelina, AR Macquarie Park, AU Minsk, BY Antwerpen, BE Sao Paulo, BR Dupnica, BG see more |
Employees | Employees 82,878 | Employees 38,0003% increase | Employees 94,300 | Employees 47,0009% increase | Employees 55,00010% increase | Employees 81,0008% decrease | Employees 75,883 | Employees 73,0004% increase | Employees 37,000 |
Valuation ($) | Valuation ($) 141.1 b | Valuation ($) 14 b | Valuation ($) 2.7 b | Valuation ($) 903.4 b | Valuation ($) 335 b | Valuation ($) 163.9 b | Valuation ($) N/A | Valuation ($) 294.7 b | Valuation ($) 20.8 b |
Financial | |||||||||
Revenue (est.) | Revenue (est.) €45.4b (FY, 2025) | Revenue (est.) $14.3b (FY, 2025) | Revenue (est.) $58.7b (FY, 2025) | Revenue (est.) $65.2b (FY, 2025) | Revenue (est.) $61.2b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $65b (FY, 2025) | Revenue (est.) $17.3b (FY, 2025) |
Cost of goods | Cost of goods €11.6b (FY, 2025) | Cost of goods $9.3b (FY, 2025) | Cost of goods $4.9b (FY, 2025) | Cost of goods $11.1b (FY, 2025) | Cost of goods $18.2b (FY, 2025) | Cost of goods $16.1b (FY, 2025) | Cost of goods $8.4b (FY, 2025) | Cost of goods $16.4b (FY, 2025) | Cost of goods $8.3b (FY, 2025) |
Gross profit | Gross profit €37.6b (FY, 2025) | Gross profit $5b (FY, 2025) | Gross profit $54.2b (FY, 2025) | Gross profit $54.1b (FY, 2025) | Gross profit $43b (FY, 2025) | Gross profit $46.5b (FY, 2025) | Gross profit $49.8b (FY, 2025) | Gross profit $48.6b (FY, 2025) | Gross profit $8.9b (FY, 2025) |
Net income | Net income €8b (FY, 2025) | Net income ($3.5b) (FY, 2025) | Net income $10.2b (FY, 2025) | Net income $20.6b (FY, 2025) | Net income $4.2b (FY, 2025) | Net income $7.8b (FY, 2025) | Net income $14b (FY, 2025) | Net income $18.3b (FY, 2025) | Net income $1.4b (FY, 2025) |
Operating ⚠ | |||||||||
Countries | Countries N/A | Countries 165 (Q1, 2023) | Countries 130 (FY, 2021) | Countries 120 (FY, 2021) | Countries 70 (FY, 2022) | Countries 200 (FY, 2024) | Countries N/A | Countries N/A | Countries N/A |
Manufacturing Sites | Manufacturing Sites N/A | Manufacturing Sites 40 (Q1, 2023) | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 37 (FY, 2024) | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 27 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products 51 (FY, 2024) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 8 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products 27 (FY, 2024) | Phase II Trials Products N/A | Phase II Trials Products 85 (FY, 2022) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 10 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products 32 (FY, 2024) | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 32 (FY, 2022) | Phase III Trials Products N/A |
Product Categories | Product Categories N/A | Product Categories 3 (Q1, 2023) | Product Categories N/A | Product Categories N/A | Product Categories 6 (FY, 2022) | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline 91 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 177 (FY, 2021) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 5 (FY, 2024) | Registration Phase Products 8 (FY, 2022) | Registration Phase Products N/A | Registration Phase Products N/A |
Funding | |||||||||
Total funding raised | Total funding raised $ 310m | Total funding raised N/A | Total funding raised $ 1b | Total funding raised N/A | Total funding raised $ 3.8b | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised $ 358m |
For sources of this data, please see the company profile
View Company Profiles
Viatris
HQ
Canonsburg, US
Employees
38,000↑ 3% increase
Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products.
View companyAstraZeneca
HQ
Cambridge, GB
Employees
94,300
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
View companyLilly
HQ
Indianapolis, US
Employees
47,000↑ 9% increase
Eli Lilly is a company that discovers, develops, manufactures, and markets pharmaceutical products.
View companyAbbVie
HQ
North Chicago, US
Employees
55,000↑ 10% increase
AbbVie is a pharmaceutical company engaged in the research, development, manufacturing, commercialization, and sale of medicines and therapies.
View company